Savara (SVRA)
NASDAQ:SVRA
Want to see SVRA full AI Analyst Report?
SVRA Stock Chart & Stats
$5.78
$0.04(1.15%)
At close: 4:00 PM EST
$5.78
$0.04(1.15%)
Day’s Range― - ―
52-Week Range$1.89 - $7.01
Previous CloseN/A
Volume189.20K
Average Volume (3M)1.67M
Market Cap
$1.08B
Enterprise Value$1.05B
Total Cash (Recent Filing)$235.70M
Total Debt (Recent Filing)$29.91M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
May 07, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding204,657,500
10 Day Avg. Volume1,139,092
30 Day Avg. Volume1,667,003
Financial Highlights & Ratios
PEG Ratio-1.08
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-788.47
Enterprise Value/Ebitda-8.60
Forecast
1Y Price Target
$11.00Price Target Upside90.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$16.54M
Bulls Say, Bears Say
Bulls Say
Addressable Market ExpansionA simple finger‑prick antibody test is revealing many previously missed cases of autoimmune pulmonary alveolar proteinosis, indicating a substantially larger pool of diagnosable patients and potential market growth if approved.
Clinical EvidenceClinical trials produced robust, durable improvements in lung function and respiratory outcomes with publications in leading medical journals and strong endorsement from pulmonary key opinion leaders, reinforcing confidence in the therapy's benefit.
Regulatory PathwayU.S. regulator granted Priority Review for the biologics application and confirmed no advisory committee meeting while not citing safety or efficacy concerns, supporting a more streamlined path toward potential approval.
Bears Say
Launch Timing RiskThe FDA's extended review following a major amendment delays potential market launch and increases uncertainty around revenue timing, raising event‑driven risk for the stock.
Manufacturing And Regulatory ExecutionOutstanding chemistry and manufacturing reviews, potential inspections, and the risk of labeling or manufacturing issues represent material regulatory and execution risks that could impede approval or commercialization.
Reimbursement And Adoption HurdlesPersistent insurance denials, high patient copays, and reliance on whole lung lavage as the standard initial treatment could limit patient access and constrain uptake even after an approval.
Savara News
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $1.89 and its highest was $7.00 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $1.08B.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is May 07, 2026 which is in 14 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on Mar 13, 2026. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.119 by -$0.011.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.14.
How many shares outstanding does Savara have?
Savara has 204,657,500 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.119. Following the earnings report the stock price went down -1.316%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Savara Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (90.31% Upside)
$11.00 (90.31% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 9.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 13.6%
Last 30 Days ▲ 13.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.02%
12-Months-Change
Fundamentals
Return on Equity
-84.01%
Trailing 12-Months
Asset Growth
19.05%
Trailing 12-Months
Company Description
Savara
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
SVRA Stock 12 Month Forecast
Average Price Target
$11.00
▲(90.31% Upside)
Technical Analysis
Ownership Overview
3.07% Insiders
7.18% Mutual Funds
0.16% Other Institutional Investors
78.95% Public Companies and
Individual Investors